- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD…
INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administrationEnriched IP…
Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and…
Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a…
World-first take-home approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE /…
STOCKHOLM, SE / ACCESSWIRE / August 24, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR)…
New South San Francisco Location Offers CleanSuites, Broadening Scope of Lab Capabilities to Span Early-Stage R&D through Product CommercializationBOSTON, MA…
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights…
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated…
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified…